Search Results
You are looking at 1 - 1 of 1 items for :
- Author: Miles Levy x
- Pituitary and Hypothalamus x
Search for other papers by The Working Group for Renaming Diabetes Insipidus in
Google Scholar
PubMed
Japan Endocrine Society
Search for other papers by Hiroshi Arima in
Google Scholar
PubMed
European Society for Pediatric Endocrinology
Search for other papers by Timothy Cheetham in
Google Scholar
PubMed
European Society of Endocrinology
Search for other papers by Mirjam Christ-Crain in
Google Scholar
PubMed
Search for other papers by Deborah Cooper in
Google Scholar
PubMed
Wellcome-MRC Institute of Metabolic Science, University of Cambridge & Addenbrooke’s Hospital, Cambridge Biomedical Campus, Cambridge, UK
Search for other papers by Mark Gurnell in
Google Scholar
PubMed
Brazilian Society of Endocrinology and Metabolism
Search for other papers by Juliana B Drummond in
Google Scholar
PubMed
Society for Endocrinology
Search for other papers by Miles Levy in
Google Scholar
PubMed
Endocrine Society of Australia
Search for other papers by Ann I McCormack in
Google Scholar
PubMed
Endocrine Society
Search for other papers by Joseph Verbalis in
Google Scholar
PubMed
Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK
Search for other papers by John Newell-Price in
Google Scholar
PubMed
Pituitary Society
Search for other papers by John A H Wass in
Google Scholar
PubMed
‘What’s in a name? That which we call a rose/By any other name would smell as sweet’ (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word, and it therefore represents a convention with no intrinsic meaning. While this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rationale for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology, and pediatric endocrine societies now proposes changing the name of ‘diabetes insipidus’ to ‘arginine vasopressin deficiency (AVP-D)’ for central etiologies, and ‘arginine vasopressin resistance (AVP-R)’ for nephrogenic etiologies. This article provides both the historical context and the rationale for this proposed name change.